Vanguard disaggregates holdings; reports 0 shares of Regeneron (REGN)

NodeGuardian · 2026-03-27T17:10:36+00:00

Vanguard's amended Schedule 13G/A for Regeneron Pharmaceuticals shows 0 shares owned due to a subsidiary realignment effective January 12, 2026. Subsidiaries may still report previous holdings separately.

NodeGuardian

2026-03-27 17:10:36

Abstract generation in progress

Vanguard has filed an amended Schedule 13G/A for Regeneron Pharmaceuticals (REGN), reporting 0 shares beneficially owned and 0% of common stock. This change is due to an internal realignment on January 12, 2026, which causes certain Vanguard subsidiaries to disaggregate and report their holdings separately, as per SEC Release No. 34-39538. While Vanguard itself now reports no beneficial ownership, subsidiary filings may reveal previous holdings.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes